87 results about "Ternary complex" patented technology

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The present invention provides a binary or ternary complex. The complex can improve the stability of a drug, and in particular, inhibit the transesterification reaction within drug molecules. The complex can also improve the efficacy formulation performance of the drug, improving the safety and effectiveness of the drug.

The invention discloses a digital single-molecule enzyme multi-activity characteristic cross-scale heterogeneity dynamic evaluation method, which comprises the following steps: diluting a pre-combined enzyme-template-primer ternary complex to a single-molecule level so as to load the enzyme-template-primer ternary complex into a reaction chamber in a micropore array chip for rolling circle amplification, a molecular beacon is combined with an amplification product to release a fluorescence signal; monitoring and acquiring the fluorescence signal in real time to generate a time-resolved fluorescence intensity curve; extracting a slope parameter of the fluorescence intensity curve so as to obtain a catalytic synthesis rate through conversion calculation for evaluating enzyme activity; the distribution of catalytic synthesis rate values is fitted using an n-fold Gaussian mixture model to obtain a standard deviation for assessing population homogeneity and a coefficient of variation for assessing stability. According to the invention, cross-scale analysis of single-molecule resolution, multi-parameter dynamic association and environmental interference processing can be realized at the same time, and resolution limitation of a traditional analysis technology is broken through by integrating single-molecule fluorescence tracking and population statistics.

This invention discloses a protein-polysaccharide ternary nanoparticle loaded with cordycepin, its preparation method, and its applications. The invention employs a layer-by-layer self-assembly method to modify the surface of zein nanoparticles. Since zein has a positive surface charge, the first layer modification uses the anionic polysaccharide sodium alginate for electrostatic bonding, and the second layer modification uses the cationic polysaccharide chitosan, constructing positively charged ternary composite nanoparticles. These nanoparticles have small particle size, high encapsulation efficiency, high drug loading capacity, and a sustained-release effect, significantly reducing cytotoxicity and significantly improving the therapeutic effect on osteoarthritis. This invention develops a novel cordycepin formulation, overcoming the limitations of cordycepin's clinical use.

The invention relates to the technical field of compositions of high-molecular compounds, and particularly discloses a preparation method of a sodium caseinate-epigallocatechin gallate-iron ion ternary complex as well as a product and application thereof. The preparation method comprises the following steps: S1, adding EGCG (epigallocatechin gallate) into an SC solution, and stirring in a shading environment to obtain a binary compound; s2, adding a FeCl3. 6H2O solution into the binary compound, and stirring in a shading environment to obtain a ternary compound; wherein in the ternary complex, the mass ratio of SC to EGCG to Fe < 3 + > is (10-14): 1: (2-4). According to the preparation method disclosed by the invention, the stable ternary complex can be prepared, the ternary complex utilizes the metal phenolic network to modify the sodium caseinate, and a high internal phase emulsion formed after the sodium caseinate is loaded with the beta-carotene can show excellent stability and relatively high encapsulation efficiency, so that the bioavailability of the beta-carotene can be remarkably improved.

The invention provides a protein-polysaccharide-polyphenol ternary complex used as a Pickering emulsifier and a preparation method of the protein-polysaccharide-polyphenol ternary complex. Specifically, the ternary complex is a complex formed by whey protein nanofibers and a pectin-polyphenol covalent complex. The ternary complex provided by the invention has very excellent interface stabilizer / active agent performance, and can be used as an emulsifier / interface stabilizer / interface active agent of Pickering emulsion.

The invention relates to the technical field of functional drinks, in particular to a polypeptide synergistically strengthened cubilose collagen composite drink with a breast enlarging function and a preparation method of the polypeptide synergistically strengthened cubilose collagen composite drink. The drink contains fish collagen tripeptide, elastin peptide, cubilose peptide, pueraria mirifica isoflavone, red clover isoflavone and saffron crocus extract. A lipidosome delivery system is adopted to entrap polypeptide to form a nano-scale compound, nano-emulsion entraps phytoestrogen, and berry polyphenol and lipidosome-polypeptide form a stable ternary compound. Through the multi-way synergistic effect that phytoestrogen activates a mammary gland estrogen receptor, polypeptide promotes connective tissue collagen synthesis and cubilose peptide activates a growth factor signal, mammary gland development is remarkably promoted, the breast enlarging effect is achieved, the bioavailability reaches 85% or above, and the retention rate of active ingredients stored at normal temperature for 24 months is larger than 90%.

The invention discloses a PROTAC chimera for targeted degradation of an ROR [gamma] t receptor and application of the PROTAC chimera, the structure of the chimera is RW-L-Re, Re is a ligand capable of being combined with E3 ubiquitin ligase, L is a linking group covalently combined with at least one Re and at least one RW, and Rw is a target protein ROR [gamma] t binding ligand and is selected from one of the following structures. A series of PROTAC chimeras capable of degrading an ROR gamma t receptor in a targeted manner are designed and synthesized for the first time, a ternary complex is formed mainly by combining a target protein ligand and an E3 ubiquitin ligase ligand with POI and E3 ligase respectively, and then the POI is labeled with a ubiquitination tag and is further degraded by proteasome. Experimental results prove that the PROTAC chimera designed by the invention has excellent ROR [gamma] t receptor degradation activity, and can be used for preparing related drugs for treating autoimmune diseases or tumors.

The invention discloses a medicinal and edible active component-small molecule peptide-nano-selenium synergistic anti-aging composition screened based on a molecular docking technology, and belongs to the technical field of functional foods and biological medicines. The composition comprises an active ingredient with homology of medicine and food, a specific molecular polypeptide Ala-Val-His-Leu-Cys-Gly-Phe-Asp-Glu-Ser-Thr-Lys-Arg-Tyr-Pro and nano-selenium, wherein the active ingredient with homology of medicine and food is screened by a molecular docking technology and is combined with senescence-related targets Nrf2 and / or SIRT1 in a high affinity manner, and the active ingredient, the specific molecular polypeptide and the nano-selenium form an active ingredient-molecular polypeptide-nano-selenium ternary complex with homology of medicine and food. The preparation method comprises the following steps: screening the medicinal and edible active ingredients meeting conditions, preparing the molecular polypeptide, mixing the medicinal and edible active ingredients to form a compound, adding the nano-selenium, stirring and combining, and freeze-drying to obtain a finished product. The composition can be prepared into an oral preparation or an external preparation, has a multi-dimensional synergistic efficient anti-aging effect of an active ingredient targeted activation pathway, direct anti-oxidation of nano-selenium and enhanced delivery of a peptide carrier, and is suitable for preparation of anti-aging drugs or functional foods.

The present invention provides a quantitative measurement method using competitive immunochromatography, which has not been previously reported. The quantitative measurement method comprises: (1) creating a calibration curve based on the signal intensity of a test line according to the concentration of a standard material by using multiple strips, and calculating the concentration of a target analyte by using the calibration curve; (2) when the concentration of the target analyte increases to a significant level on the calibration curve of the standard material, a labeled signal of a detection ligand on a control line remains unchanged in a case where a detection ligand of a target analyte-detection ligand conjugate binds to and saturates a capture ligand on the control line, making it impossible to estimate the concentration beyond that level; however, by designing a binding site for the capture ligand on the control line to be the target analyte of the target analyte-detection ligand conjugate, a high concentration of the target analyte breaks down the triple conjugate of detection ligand-target analyte-capture ligand, leading to dissociation of the labeled detection ligand and thereby weakening the signal (hook effect); and (3) comparing the signal intensity patterns of the test line and the control line according to the calibration curve of the standard material with the signal intensity pattern of a sample target analyte, and determining how far the target analyte is from the saturation point of the detection ligand. This method is characterized in that, in cases where the target analyte is present in an excessively large amount and exceeds the maximum value of a measurement range (dynamic range) of the calibration curve, the calibration curve using multiple strips and the configurations (test line and control line) of an immunochromatographic device are designed differently to distinguish such cases.

The application discloses a PROTAC compound with RORgamma t receptor targeted degradation and purposes thereof, which is a compound with a structure shown in a general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. e is a ligand capable of combining with an E3 ubiquitin ligase; the L is a linking group covalently combining at least one R e and at least one R W ; the R w is a target protein RORgamma t binding ligand; the application is based on the target point of RORgamma t and the PROTAC technology, and a series of RORgamma t-PROTACs are designed and synthesized for the first time. The mechanism is that the target protein ligand and the E3 ubiquitin ligase ligand are combined with POI and E3 ligase respectively, so as to form a ternary complex of "POI-PROTAC-E3 ligase". Then, the POI is marked with a ubiquitination label, and is degraded by a proteasome. The advantages of RORgamma t-PROTACs mainly include targeting of "undruggable proteins", small dosage, low toxicity, and difficulty in drug resistance. W -L-R e (I)

The application discloses a novel multifunctional resistant starch rich in active small-molecule ternary complex, a one-step induction synchronous preparation process and application thereof. By introducing lipids with a certain structure, phenolic compounds without long alkyl chains and starch form inclusion complexes with V-shaped ordered structures. By adjusting the addition sequence of lipids and phenolic compounds in the preparation process and optimizing the process parameters, multifunctional resistant starch with high phenolic loading rate and strong antioxidant activity is prepared by one-step induction. The application breaks through the technical bottleneck that phenolic compounds without long alkyl chains are difficult to form V-shaped complexes with starch, significantly improves the complexing efficiency of starch and phenolic compounds without long alkyl chain structure, and improves the content of active small-molecule phenols in the complex. Compared with the prior art, the prepared complex has stronger DPPH free radical scavenging effect, shows better digestion resistance and antioxidant effect, and can be used in the fields of functional food, nutritional additives and the like for reducing postprandial blood glucose, antioxidant and the like.

This invention belongs to the field of food processing technology, specifically relating to a walnut protein isolate-xanthan gum-epigallocatechin gallate ternary complex, emulsion, its preparation method, and its application. The walnut protein isolate-xanthan gum-epigallocatechin gallate ternary complex in the composite emulsion provided by this invention exhibits reduced particle size, enhanced electrostatic repulsion, and the absence of uneven clumps and particles. The elasticity and viscosity of the composite emulsion are significantly enhanced, and the complex demonstrates comprehensive environmental stability over a wide range of pH, salt concentration, and temperature conditions.

The invention relates to the field of bioengineering, in particular to a construction method and application of an amylopectin ternary nano assembly with a high assembly index. The invention provides a construction method of a ternary nano assembly. The construction method comprises the following steps: S1, extracting amylopectin of bulk crops by adopting an ethanol sedimentation method; s2, extracting endogenous lipids of fruits of completely mature bulk crops by adopting a supercritical carbon dioxide extraction method; s3, extracting endogenous proteins of fruits of immature bulk crops by adopting an isoelectric precipitation method; s4, the amylopectin, the endogenous lipid and the endogenous protein are subjected to a self-assembly reaction, and the ternary nano assembly is obtained. The particle size of the ternary complex can reach nanometer, and the ternary complex is high in CI, high in SDS content, low in multi-stage digestion rate, stable in blood sugar release process and good in chewiness.

The present application relates to the technical field of oyster peptides, and specifically to a method for preparing oyster peptides and their use in improving male reproductive function. The present application utilizes oyster peptides as raw materials, grafts oleanolic acid saponins thereon, and composites them with chitosan to prepare an emulsion of a ternary complex. The emulsion can form stable microscopic particles and has stable rheological properties. Through simulated digestion experiments, it was found that the emulsion has a sustained-release effect on the digestion of oyster peptides, and can at least reduce the proportion of digestion in the oral cavity. In addition, the use of the emulsion and the oyster peptide to intervene in rats with nephrotic syndrome can effectively alleviate their nephrotic syndrome, and at the same time promote the male sexual function of rats, and has an application prospect of modifying and improving male reproductive function.

This invention relates to the field of emulsion technology, specifically disclosing a method for preparing a casein micelle-phenol-whey protein ternary complex, comprising: S1, screening bovine milk with κ-casein genotype AA, and using it as raw material to prepare a casein micelle solution; S2, adding a phenolic compound to the casein micelle solution to form a casein micelle-phenol binary complex mixed solution; S3, dialyzing the mixed solution obtained in step S2; S4, adding whey protein; by combining a phenolic compound (such as EGCG) with casein micelles and whey protein to form a ternary complex, the degree to which proteins form dense clots in the stomach can be reduced, making the clot structure looser, thereby accelerating the digestion rate and reducing stomach discomfort.

This invention relates to the field of pharmaceutical technology, and discloses a stress particle targeted degrader, its preparation method, and its applications. The compounds provided by this invention include ternary complexes composed of stress particle protein, a linker group, and an E3 ubiquitin ligand, or ternary complexes composed of stress particle protein, a linker group, and a ribonuclease L ligand. Compounds with different ligands exhibit good targeting and degradation effects on stress particles and can be used as stress particle targeted degraders in the preparation of antitumor drugs and anti-neurodegenerative disease drugs, showing promising application prospects in treating stress particle-induced tumor drug resistance and neurodegenerative diseases.

Methods, compositions, kits and apparatuses that include a fluid, the fluid containing a ternary complex and Li+, wherein the ternary complex includes a primed template nucleic acid, a polymerase, and a nucleotide cognate for the next correct base for the primed template nucleic acid molecule. As an alternative or addition to Li+, the fluid can contain betaine or a metal ion that inhibits polymerase catalysis such as Ca2+. In addition to Li+, the fluid can contain polyethylenimine (PEI) with or without betaine.

The invention relates to the technical field of biological medicine, in particular to a multifunctional ternary complex based on cyclodextrin and a preparation method thereof. The invention provides a multifunctional curcumin / methotrexate ternary complex based on beta-cyclodextrin. The ternary complex can realize synergistic delivery and controlled-release release of natural polyphenol and synthetic drugs in a medication mode of'one dose with multiple effects'. Meanwhile, the problems that a traditional medicine is poor in water solubility and low in bioavailability, the treatment effect of a single medicine is limited, and an existing nano delivery system is complex in structure, tedious in preparation and the like are solved, and the technical requirements of modern medicine preparations are met.

Compounds containing aziridine moieties and methods for their synthesis are provided. The compounds can bind to monovalent organic moieties and can be used to bind targets (e.g., target proteins), such as by crosslinking the targets. In some embodiments, the monovalent organic moiety is capable of binding to a presenting protein. Also disclosed are complexes (e.g., presenting protein / compound complexes, compound / target protein complexes, or triple complexes) containing the compounds. Methods of forming the complexes and methods of modulating biological processes using the compounds and complexes are also disclosed.

The invention provides an SPI-CS-EGCG ternary complex as well as a preparation method and application thereof. The preparation method of the ternary complex comprises the following steps: respectively preparing an SPI solution, a CS solution and an EGCG solution; adjusting the pH value of the SPI solution, and heating to obtain SPI microgel; the SPI microgel and a CS solution are mixed and stirred, and an SPI-CS mixed solution is obtained; and mixing and stirring the SPI-CS mixed solution and the EGCG solution, and centrifuging to obtain the SPI-CS-EGCG ternary complex. According to the SPI-CS-EGCG ternary complex, the functional characteristics of SPI are remarkably improved through non-covalent interaction (hydrogen bonds, hydrophobic interaction and Van der Waals' force), and the SPI-CS-EGCG ternary complex has good thermal stability, rheology and tribology characteristics, so that the SPI-CS-EGCG ternary complex has wide application prospects in the food industry.

This invention provides a ready-to-drink milk tea based on a ternary complex stabilized with κ-casein genotype and its preparation method, belonging to the field of dairy processing technology. It includes a ternary complex of casein micelles containing AA genotype κ-casein, epigallocatechin gallate, and fructose. The preparation of the ready-to-drink milk tea includes the following steps: S1: raw material screening and pretreatment; S2: preparation of the ternary complex; S3: blending and processing of the ready-to-drink milk tea. By screening AA genotype κ-casein raw milk and using a specific sequence of first compounding EGCG and then grafting fructose, a casein micelle-EGCG-fructose ternary complex with uniform structure and controllable particle size is constructed. Fructose is further grafted onto the surface of the complex through glycosylation, effectively masking the excessive binding sites of proteins and polyphenols, significantly inhibiting the formation of insoluble aggregates, thereby maintaining excellent colloidal stability of the product during its shelf life.

The invention provides a rare earth organic acid salt complex with high far infrared emissivity and a preparation method and application thereof, the molecular general formula of the rare earth organic acid salt complex is RE (OA-SH) 3 (Phen), RE is a rare earth ion, OA-SH is a functionalized oleic acid ligand, Phen is phenanthroline, and the functionalized oleic acid ligand is 11-mercaptoundecane-9-olefine acid. According to the invention, the ternary complex with a clear structure is successfully constructed through a multi-step reaction. Compared with simple neodymium oleate, the ternary complex has the advantage that the far infrared emissivity can be increased from 0.92 to 0.97.

The application discloses a Cas protein PAM analysis method based on local geometric structure and machine learning, and belongs to the fields of biotechnology and artificial intelligence. The method comprises the following steps: constructing an initial structure of a Cas protein-DNA-RNA ternary complex by using a structure prediction tool, and generating a mutant structure data set containing different PAM sequences by calculation and optimization; extracting and embedding the local structure of a PAM site to obtain a structure feature vector, performing dimension reduction and cluster analysis by using an unsupervised machine learning method, realizing natural classification of the PAM sequence, and identifying the cluster result in combination with P prior biological knowledge. The application creatively combines the three-dimensional local geometric structure of a protein and machine learning, can predict and classify the PAM preference of a Cas protein from a structure source, has the advantages of objectivity, comprehensiveness, and the ability to reveal hidden patterns, and can be verified by experimental data.

The invention discloses a molecular glue drug screening method and application in degradable drug screening. A molecular gel drug screening method comprises the following steps: preparing a compound library into a first microarray chip, and screening compounds combined with effect protein based on an OI-RD image to obtain a first candidate; preparing a second microarray chip, measuring binary binding kinetics of the first candidate and the effect protein based on an OI-RD optical real-time signal, and verifying to obtain a second candidate; and preparing a third microarray chip, and screening a compound subjected to the ternary reaction based on an OI-RD real-time signal of the ternary reaction. According to the screening method disclosed by the invention, by directly detecting the formation of the target protein-molecular glue-effect protein ternary complex, the screening accuracy is remarkably improved, the type of the molecular glue which is not directly combined with the target protein can be effectively identified, and molecular glue screening with higher specificity and higher flux is realized.

The present disclosure discloses a ternary protein-based composite system and the preparation method thereof, relating to the fields of functional foods and pharmaceuticals. Compared to a single soy protein isolate and the binary complexes thereof, the ternary composite systems SLE-7, SEL-7, SLE-9, SEL-9 exhibit significant changes in protein structure and stronger interactions. Studies shows that pH value and the addition sequence of raw materials significantly impact the particle size of the complexes and functional properties of the composite systems. At pH 7, SLE-7 shows the highest EAI and ESI among ternary complexes; at pH 9, SEL-9 shows the highest EAI and ESI among the ternary systems; SEL-9 possesses the smallest particle size and the most uniform system, with its composite emulsion demonstrating optimal emulsifying performance, making it suitable for application in functional foods and pharmaceuticals.

The present application provides a soluble dietary fiber composition, its preparation method and application. After the soluble dietary fiber composition enters the colon, the ester bond in the alanine modified pectin is rapidly degraded, part of the chlorogenic acid is released, the secretion of anorectic hormone is stimulated, the appetite is reduced, and the heat intake is reduced; the remaining amide bond network is slowly degraded, realizing the slow and continuous release of chlorogenic acid. Lutein removes free radicals generated by fat decomposition, reducing the oxidative damage of L cells. Galactomannan and alanine modified pectin-glucan modified protein-chlorogenic acid ternary complex synergize to improve the molar ratio of butyric acid / propionic acid: propionic acid enhances satiety through intestinal gluconeogenesis, and butyric acid stimulates the secretion of GLP-1 / PYY, realizing endogenous appetite suppression. Galactomannan absorbs water to form a lubricating gel, softening the stool and increasing the stool volume; the ternary complex degrades to produce short-chain fatty acids, optimizing the intestinal microenvironment and enhancing gastrointestinal peristalsis, both of which synergistically improve constipation.

The application discloses a kind of digital single molecule enzyme multi-activity characteristic cross-scale heterogeneity dynamic evaluation methods, comprising: the enzyme-template-primer ternary complex of pre-combination completion is diluted to single molecule level to be loaded into the reaction chamber in microwell array chip to carry out rolling circle amplification, and utilize molecular beacon and the fluorescence signal released by amplification product combination;Real-time monitoring and obtaining the fluorescence signal to generate time-resolved fluorescence intensity curve;The slope parameter of the fluorescence intensity curve is extracted to obtain the catalytic synthesis rate by conversion calculation for evaluating enzyme activity;The catalytic synthesis rate value distribution is fitted using n times Gaussian mixture model to obtain the standard deviation for evaluating population uniformity and the coefficient of variation for evaluating stability.The application can realize single molecule resolution, multi-parameter dynamic correlation and environmental interference processing cross-scale analysis simultaneously, and break through the resolution limit of traditional analysis technology by integrating single molecule fluorescence tracking and population statistics.

This invention provides the application of chlorogenic acid in the preparation of drugs for treating intranuclear inclusion body disease (NIID), belonging to the field of pharmaceutical technology. This invention utilizes widely available sources with abundant safety data. Compared to novel chemical entities, chlorogenic acid, with its lower development risk, is used as a raw material. It has been found that chlorogenic acid can enhance the interaction between polyG protein and the E3 ubiquitin ligase TRIM21, forming a stable TRIM21-chlorogenic acid-polyG ternary complex. This promotes polyG ubiquitination and proteasome-dependent degradation, thereby reducing intracellular inclusion body burden and alleviating NIID from its pathological root cause. This provides a safe, effective, and highly specific new targeted therapeutic strategy for NIID.

The present invention features compounds containing an aziridine moiety and methods for synthesizing the same. The compounds can be linked to a monovalent organic moiety and can be used to bind to a target (e.g., a target protein), e.g., by crosslinking to the target. In some embodiments, the monovalent organic moiety is capable of binding to a presenter protein. Also disclosed are complexes containing the compounds (e.g., presenter protein / compound complexes, compound / target protein complexes, or ternary complexes). Also disclosed are methods of forming the complexes and methods of modulating biological processes using the compounds and complexes.